SVA
Sinovac Biotech Ltd
6.50$
+0.0%
vs. previous close
Closing price · As of: Sep 12, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 64.9% | 63.3% | 63.5% | 61.9% | 76.8% | 77.3% | 82.1% | 89.1% | 85.9% | 86.6% | 86.3% | 81.8% | |
| 38.3% | 31.5% | 29.5% | 29.5% | 42.8% | 33.8% | 54.8% | 69.3% | 30.3% | 9.3% | 2.7% | 13.4% | |
| 38.3% | 31.5% | 29.5% | 29.5% | 47.9% | 44.9% | 61.9% | 80.1% | 80.1% | 82.2% | – | 76.9% | |
| 17.1% | 19.2% | 23.6% | 23.6% | 20.9% | 25.1% | 13.3% | 5.7% | 4.3% | 3.3% | 2.4% | 3.6% | |
| 7.8% | 9.2% | 6.7% | 6.7% | 6.8% | 6.2% | 5.6% | 2.2% | 1.3% | 1.0% | 0.8% | 1.1% | |
| 28.7% | 31.5% | 31.6% | 36.2% | 19.2% | 17.9% | 14.9% | – | – | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 0.2% | 0.1% | |
| 4.4% | 4.7% | 4.1% | 4.1% | 2.2% | 1.8% | 0.5% | 0.2% | 0.6% | 0.1% | 1.5% | 0.9% | |
| 40.6% | 32.7% | 38.7% | 38.7% | 21.1% | 22.1% | 41.1% | 17.1% | 9.9% | 12.0% | 16.6% | 25.9% | |
| 33.5% | 28.6% | 31.4% | 31.4% | 15.7% | 19.3% | 35.7% | 14.4% | 7.7% | 8.4% | 11.8% | 17.8% | |
| 20.9% | 11.9% | 15.9% | 15.9% | 0.9% | 2.9% | 2.2% | 0.1% | 0.1% | 0.6% | – | 2.7% | |
| 1.3% | 0.8% | 0.9% | 0.9% | 1.5% | 1.3% | 1.6% | 0.3% | 0.1% | 0.1% | 0.1% | 0.2% | |
| 0.8% | 0.4% | 4.5% | 7.0% | 1.1% | 0.3% | 0.4% | 0.1% | 0.1% | 1.3% | 1.3% | 3.1% | |
| 53.1% | 59.9% | 61.3% | 61.3% | 68.5% | 65.0% | 39.3% | 55.7% | 63.2% | 63.8% | 67.0% | 51.4% | |
| -2.7% | -4.9% | -5.6% | -5.6% | 6.4% | 12.5% | 7.6% | 42.6% | 51.2% | 52.1% | 55.4% | 32.6% | |
| 23.3% | 27.8% | 26.9% | 26.9% | 17.6% | 24.3% | 6.0% | 0.7% | 0.8% | 0.7% | 0.6% | 0.8% |
Data as of: September 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.